AN2 Therapeutics is a California-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of chronic and infectious diseases.
Business Model:
Revenue: $0
Employees: 11-50
Address: 1800 El Camino Real
City: Menlo Park
State: CA
Zip: 94027
Country: US
AN2 Therapeutics is a California-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of chronic and infectious diseases.
Contact Phone:
+16503319090
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
3/25/2022
Ticker Symbol:
ANTX
IPO Price:
$15/share
Amount Raised:
$69M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2022 | IPO | $73.6M |
|
11/2019 | Series A | $0 |
Brii Biosciences BioRock Ventures Adjuvant Capital Mountain Group Capital Mountain Group Capital Brii Biosciences BioRock Ventures Adjuvant Capital Mountain Group Capital Mountain Group Capital |
1/2022 | Series B | 6 | $80M |
Avidity Partners Monashee Investment Management Surveyor Capital BVF Partners Hatteras Venture Partners RA Capital Management RA Capital Management Avidity Partners Monashee Investment Management Surveyor Capital BVF Partners Hatteras Venture Partners RA Capital Management RA Capital Management |
11/2019 | Series A | 4 | $12M |
Mountain Group Partners Adjuvant Capital Brii Biosciences BioRock Ventures Brii Biosciences BioRock Ventures Adjuvant Capital Mountain Group Capital Mountain Group Capital |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|